Without 'smoking gun,' BMS, Celgene deal will close as planned: analyst

Bristol-Myers Squibb
Bristol-Myers Squibb and Celgene announced their $74 billion tie-up in January. It's one of pharma's biggest-ever mergers. (Bristol-Myers Squibb)

Bristol-Myers Squibb and Celgene executives have been working hard to defend their $74 billion merger against dissident shareholders, and on Tuesday, the sides rolled out more arguments either for or against the deal. But despite staunch disagreement over the merits of the merger, at least one analyst still believes the deal will go through after a vote on April 12. 

Starboard Value published a 197-page presentation on Tuesday criticizing the proposed megamerger as “ill-advised” and hurried, arguing it could destroy shareholder value. But the investors didn’t present a “smoking gun,” Jefferies analyst Michael Yee wrote in a note to clients, so the way he sees it, the deal is still likely to get support from advisers at Institutional Shareholder Services and go through. 

Blasting the deal, Starboard said Bristol executives seem to have rushed the talks out of a desire to “announce the acquisition by an arbitrary near-term deadline.” Further, Starboard said the merger was negotiated with the “wrong intentions, as a defensive measure designed to protect Bristol-Myers from becoming an acquisition target itself.” 

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Starboard isn't the only one that thinks the merger may have been designed to ward off unwanted BMS suitors. Wolfe Research's Tim Anderson wrote recently that he suspects the company's "actions are in fact partly designed to prevent itself from being acquired.”

RELATED: Can BMS rebels scuttle its Celgene buy? Analysts do the math—and so far, the votes don't add up

But BMS executives have their own arguments in favor of the deal, which they laid out in a Tuesday presentation. They once again stressed that the combined company would be the top player in oncology and cardiovascular diseases, plus a top-5 company in immunology and inflammation. It’d have nine products with over $1 billion in annual sales plus six near-term launches. BMS also said it went through a 6-month “deep-dive analysis” on Celgene’s opportunities and risks. 

BMS and Celgene unveiled their megamerger in early January, presenting numerous arguments about why the companies are better off together than separate. It took activist investors about a month and a half to go public with their opposition. Wellington Management—Bristol-Myers' largest shareholder—and Starboard came out against the proposal in late February.  

RELATED: What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all 

Despite the pushback, Yee and other analysts have remained confident the deal will go through. After Wellington voiced its public opposition, Atlantic Equities analysts published a note tallying up potential "no" votes and found that the rebels likely didn't have enough to scrap the deal. 

Wellington has “investment discretion” over nearly 8% of BMS’ outstanding shares, but it has shared voting power over only 1.7% of them, the analysts wrote. Another investor group, Dodge & Cox, reportedly opposes the deal, but it holds just 2.6% of BMS shares, the analysts wrote. Starboard Value's voting power is even more limited, they said. 

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.